140 related articles for article (PubMed ID: 35442101)
1. "It's Like You Stuck a Pin in It:" African American/Black Patients Describe Cutaneous Toxicity From Epidermal Growth Factor Receptor Inhibitors.
Tran NH; Nguyen PL; Martin NA; Asiedu G; Le-Rademacher JG; Jatoi A
Am J Hosp Palliat Care; 2023 Mar; 40(3):337-340. PubMed ID: 35442101
[No Abstract] [Full Text] [Related]
2. Cutaneous Manifestations of EGFR-Inhibitors in African Americans and Treatment Considerations.
Geisler AN; Noor SJ
J Drugs Dermatol; 2020 Sep; 19(9):894-896. PubMed ID: 33026750
[TBL] [Abstract][Full Text] [Related]
3. Skin problems and EGFR-tyrosine kinase inhibitor.
Kozuki T
Jpn J Clin Oncol; 2016 Apr; 46(4):291-8. PubMed ID: 26826719
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer.
Gisondi P; Geat D; Mattiucci A; Lombardo F; Santo A; Girolomoni G
Dermatology; 2021; 237(6):929-933. PubMed ID: 33508823
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors.
Hofheinz RD; Deplanque G; Komatsu Y; Kobayashi Y; Ocvirk J; Racca P; Guenther S; Zhang J; Lacouture ME; Jatoi A
Oncologist; 2016 Dec; 21(12):1483-1491. PubMed ID: 27449521
[TBL] [Abstract][Full Text] [Related]
6. EGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effects.
Recuero JK; Fitz JR; Pereira AA; Bonamigo RR
An Bras Dermatol; 2023; 98(4):429-439. PubMed ID: 36990917
[TBL] [Abstract][Full Text] [Related]
7. Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients.
Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Steffens M; Scholl C; Hichert V; Seufferlein T; Stingl JC
Eur J Cancer; 2014 Jul; 50(11):1855-63. PubMed ID: 24857781
[TBL] [Abstract][Full Text] [Related]
8. Changes in sebum levels and the development of acneiform rash in patients with non-small cell lung cancer after treatment with EGFR inhibitors.
Nakahara T; Moroi Y; Takayama K; Itoh E; Kido-Nakahara M; Nakanishi Y; Furue M
Onco Targets Ther; 2015; 8():259-63. PubMed ID: 25670908
[TBL] [Abstract][Full Text] [Related]
9. Skin toxicities associated with epidermal growth factor receptor inhibitors.
Li T; Perez-Soler R
Target Oncol; 2009 Apr; 4(2):107-19. PubMed ID: 19452131
[TBL] [Abstract][Full Text] [Related]
10. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study.
Shacham Shmueli E; Geva R; Yarom N; Hubert A; Keynan R; Kedem TH; Eini M; Tamarkin D; Shirvan M
Support Care Cancer; 2019 Aug; 27(8):3027-3033. PubMed ID: 30607677
[TBL] [Abstract][Full Text] [Related]
11. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
Agirgol S; Çaytemel C; Pilanci KN
Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
[TBL] [Abstract][Full Text] [Related]
12. Palliative care experiences of adult cancer patients from ethnocultural groups: a qualitative systematic review protocol.
Busolo D; Woodgate R
JBI Database System Rev Implement Rep; 2015 Jan; 13(1):99-111. PubMed ID: 26447011
[TBL] [Abstract][Full Text] [Related]
13. Skin Toxicities with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials.
Sun W; Li J
Cancer Invest; 2019; 37(6):253-264. PubMed ID: 31303065
[TBL] [Abstract][Full Text] [Related]
14. Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.
Tan AR; Steinberg SM; Parr AL; Nguyen D; Yang SX
Ann Oncol; 2008 Jan; 19(1):185-90. PubMed ID: 17878175
[TBL] [Abstract][Full Text] [Related]
15. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.
Segaert S; Van Cutsem E
Ann Oncol; 2005 Sep; 16(9):1425-33. PubMed ID: 16012181
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center.
Yu Z; Dee EC; Bach DQ; Mostaghimi A; LeBoeuf NR
JAMA Dermatol; 2020 Oct; 156(10):1079-1085. PubMed ID: 32609305
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor Inhibitor-Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?
Lewis W; Forrestel A; Baumrin E
Cutis; 2023 Jan; 111(1):18-21. PubMed ID: 36947773
[TBL] [Abstract][Full Text] [Related]
18. Rash management and treatment persistence of cancer patients treated with epidermal growth factor receptor inhibitors in the Truven MarketScan
Chen L; Brown J; Marmaduke DQ; Mayo C; Grau G; Lau YK; Obasaju CK
Support Care Cancer; 2018 Jul; 26(7):2369-2377. PubMed ID: 29423677
[TBL] [Abstract][Full Text] [Related]
19. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
Lacouture ME; Anadkat M; Jatoi A; Garawin T; Bohac C; Mitchell E
Clin Colorectal Cancer; 2018 Jun; 17(2):85-96. PubMed ID: 29576427
[TBL] [Abstract][Full Text] [Related]
20. [New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part B: Skin].
Ehmann LM; Heinemann V; Wollenberg A
Internist (Berl); 2011 Nov; 52(11):1359-64. PubMed ID: 21796420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
